New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies

References

• Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018.
   Google Scholar
• WHO. Global strategy to reduce harmful use of alcohol. 2016.
   Google Scholar
• GBD. 2016 alcohol collaborators, Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392(10152):1015–1035.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815–824.
   PubMed Web of Science ®Google Scholar
• Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3(8):760–773.
   PubMed Web of Science ®Google Scholar
• Goodwani S, Saternos H, Alasmari F, et al. Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder. Neurosci Biobehav Rev. 2017;77:14–31.
   PubMed Web of Science ®Google Scholar
• Soyka M. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother. 2016;17(4):619–626.
   PubMed Web of Science ®Google Scholar
• Hendrickson LM, Zhao-Shea R, Pang X, et al. Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J Neurosci. 2010;30(30):10169–10176.
   PubMed Web of Science ®Google Scholar
• Olive MF, Koenig HN, Nannini MA, et al. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J Neurosci. 2001;21(23):RC184.
   PubMed Web of Science ®Google Scholar
• Adams Z, Schacht J, Randall P, et al. The Reasons for Heavy Drinking Questionnaire: factor Structure and Validity in Alcohol-Dependent Adults Involved in Clinical Trials. J Stud Alcohol Drugs. 2016;77(2):354–361.
   PubMed Web of Science ®Google Scholar
• Hwa L, Besheer J, Kash T. Glutamate plasticity woven through the progression to alcohol use disorder: a multi-circuit perspective. F1000Res. 2017;6:298.
   PubMedGoogle Scholar
• Haass-Koffler CL, Swift RM, Leggio L. Noradrenergic targets for the treatment of alcohol use disorder. Psychopharmacology (Berl). 2018;235(6):1625–1634.
   PubMed Web of Science ®Google Scholar
• Pang TY, Hannan AJ, Lawrence AJ. Novel approaches to alcohol rehabilitation: modification of stress-responsive brain regions through environmental enrichment. Neuropharmacology. 2019;145(Pt A):25–36.
   PubMedGoogle Scholar
• Lawrence AJ, Parish CL, Chen F, et al. Chronic corticotropin-releasing factor type 1 receptor antagonism with antalarmin regulates the dopaminergic system of Fawn-Hooded rats. J Neurochem. 2005;94(6):1523–1534.
   PubMed Web of Science ®Google Scholar
• Skinner MD, Lahmek P, Pham H, et al. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9(2):e87366.
   PubMed Web of Science ®Google Scholar
• Jonas DE, Amick HR, Feltner C, et al., Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 311(18): 1889–1900. 2014. .
   PubMed Web of Science ®Google Scholar
• Rosner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(12):CD001867.
   Web of Science ®Google Scholar
• Mann K, Torup L, Sørensen P, et al. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur Neuropsychopharmacol. 2016;26(12):1941–1949.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Nalmefene for reducing alcohol consumption in people with alcohol dependence. In: Technology appraisal guidance [TA325]. 2014. United Kingdom. Available from: https://www.nice.org.uk/guidance/ta325
   Google Scholar
• Morley KC, Rombouts S, Haber P. Pharmacotherapy for alcohol use disorder. In: Guidelines for the treatment of alcohol problems, in press. Australia: Department of Health; 2020.
   Google Scholar
• Palpacuer C, Laviolle B, Boussageon R, et al., Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med. 12(12): e1001924. 2015.
   PubMed Web of Science ®Google Scholar
• Palpacuer C, Duprez R, Huneau A, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addict. 2018;113(2):220–237.
   PubMed Web of Science ®Google Scholar
• Fitzgerald N, Angus K, Elders A, et al. Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. Addict. 2016;111(8):1477–1487.
   PubMed Web of Science ®Google Scholar
• Augier E, Barbier E, Dulman RS, et al. A molecular mechanism for choosing alcohol over an alternative reward. Sci. 2018;360(6395):1321–1326.
   PubMed Web of Science ®Google Scholar
• Colombo G, Addolorato G, Agabio R, et al. Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox Res. 2004;6(5):403–414.
   PubMed Web of Science ®Google Scholar
• Walker BM, Koob GF. The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol Clin Exp Res. 2007;31(1):11–18.
   PubMed Web of Science ®Google Scholar
• Williams KL, Nickel MM, Bielak JT. Baclofen blocks yohimbine-induced increases in ethanol-reinforced responding in rats. Pharmacol Biochem Behav. 2016;144:20–25.
   PubMed Web of Science ®Google Scholar
• Maccioni P, Bienkowski P, Carai MA, et al. Baclofen attenuates cue-induced reinstatement of alcohol-seeking behavior in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend. 2008;95(3):284–287.
   PubMed Web of Science ®Google Scholar
• Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915–1922.
   PubMed Web of Science ®Google Scholar
• Rose AK, Jones A. Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addict. 2018;113(8):1396–1406.
   PubMed Web of Science ®Google Scholar
• Bschor T, Henssler J, Muller M, et al. Baclofen for alcohol use disorder-a systematic meta-analysis. Acta Psychiatr Scand. 2018;138(3):232–242.
   PubMed Web of Science ®Google Scholar
• Pierce M, Sutterland A, Beraha EM, et al. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2018;28(7):795–806.
   PubMed Web of Science ®Google Scholar
• Agabio R, Sinclair JM, Addolorato G, et al., Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry. 5(12): 957–960. 2018.
   PubMed Web of Science ®Google Scholar
• Morley KC, Baillie A, Fraser I, et al. Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial. Br J Psychiatry. 2018;212(6):362–369.
   PubMed Web of Science ®Google Scholar
• Jamshidi N, Morley KC, Cairns R, et al. A review of baclofen overdoses in Australia: calls to a Poisons Information Centre and a case series. Alcohol Alcohol. 2019;54(1):73–78.
   PubMed Web of Science ®Google Scholar
• Rolland B, Labreuche J, Duhamel A, et al. Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol. 2015;25(10):1631–1636.
   PubMed Web of Science ®Google Scholar
• Leggio L, Garbutt JC, Addolorato G. Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets. 2010;9(1):33–44.
   PubMed Web of Science ®Google Scholar
• Morley KC, Luquin N, Baillie A, et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addict. 2018;113(12):2205–2213.
   PubMed Web of Science ®Google Scholar
• Maccioni P, Colombo G. Potential of GABAB receptor positive allosteric modulators in the treatment of alcohol use disorder. CNS Drugs. 2019;33(2):107–123.
   PubMed Web of Science ®Google Scholar
• Angehagen M, Ronnback L, Hansson E, et al. Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. J Neurochem. 2005;94(4):1124–1130.
   PubMed Web of Science ®Google Scholar
• Olmsted CL, Kockler DR. Topiramate for alcohol dependence. Ann Pharmacother. 2008;42(10):1475–1480.
   PubMed Web of Science ®Google Scholar
• Guglielmo R, Martinotti G, Quatrale M, et al. Topiramate in alcohol use disorders: review and update. CNS Drugs. 2015;29(5):383–395.
   PubMed Web of Science ®Google Scholar
• Breslin FJ, Johnson BA, Lynch WJ. Effect of topiramate treatment on ethanol consumption in rats. Psychopharmacology (Berl). 2010;207(4):529–534.
   PubMed Web of Science ®Google Scholar
• Lynch WJ, Bond C, Breslin FJ, et al. Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse. Psychopharmacology (Berl). 2011;217(1):3–12.
   PubMed Web of Science ®Google Scholar
• Moore CF, Lycas MD, Bond CW, et al. Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol’s reinforcing effects in male alcohol preferring (P) rats. Exp Clin Psychopharmacol. 2014;22(1):35–42.
   PubMed Web of Science ®Google Scholar
• Blodgett JC, Del Re AC, Maisel NC, et al. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481–1488.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Armeli S, Feinn R, et al. GRIK1 genotype moderates topiramate’s effects on daily drinking level, expectations of alcohol’s positive effects and desire to drink. Int J Neuropsychopharmacol. 2014;17(10):1549–1556.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Covault J, Feinn R, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171(4):445–452.
   PubMed Web of Science ®Google Scholar
• Morley KC, Kranzler HR, Luquin N, et al. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). Trials. 2018;19(1):443.
   PubMedGoogle Scholar
• Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des. 2010;16(19):2103–2112.
   PubMed Web of Science ®Google Scholar
• Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. The Office of Quality, Safety and Value, VA, Washington, DC & Office of Evidence Based Practice, U.S. Army Medical Command, United States of America; 2015.
   Google Scholar
• Patel R, Dickenson AH. Mechanisms of the gabapentinoids and alpha 2 delta-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect. 2016;4(2):e00205.
   PubMed Web of Science ®Google Scholar
• Cai K, Nanga RP, Lamprou L, et al. The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T (1)H-MRS study. Neuropsychopharmacology. 2012;37(13):2764–2771.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Feinn R, Morris P, et al. A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addict. 2019;114(9):1547–1555.
   PubMed Web of Science ®Google Scholar
• Anton RF, Latham P, Voronin K, et al., Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med. 180(5): 728. 2020. .
   PubMed Web of Science ®Google Scholar
• Bockbrader H, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661–669.
   PubMed Web of Science ®Google Scholar
• Mersfelder T, Nichols W. Gabapetin: abuse, depdendence, and withdrawal. Ann Pharmacother. 2016;50(3):229–233.
   PubMed Web of Science ®Google Scholar
• Lyndon A, Audrey S, Wells C, et al. Risk to heroin users of polydrug use of pregabalin or gabapentin. Addict. 2019;112(9):1580–1589.
   Web of Science ®Google Scholar
• Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Jama. 2006;296(1):56–63.
   PubMed Web of Science ®Google Scholar
• Parish CL, Nunan J, Finkelstein DI, et al. Mice lacking the alpha4 nicotinic receptor subunit fail to modulate dopaminergic neuronal arbors and possess impaired dopamine transporter function. Mol Pharmacol. 2005;68(5):1376–1386.
   PubMed Web of Science ®Google Scholar
• Litten RZ, Ryan ML, Fertig JB, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J Addict Med. 2013;7(4):277.
   PubMed Web of Science ®Google Scholar
• De Bejczy A, Löf E, Walther L, et al. Varenicline for treatment of alcohol dependence: a randomized, placebo‐controlled trial. Alcohol Clin Exp Res. 2015;39(11):2189–2199.
   PubMed Web of Science ®Google Scholar
• O’Malley SS, Zweben A, Fucito LM, et al. Effect of varenicline combined with medical management on alcohol use disorder with comorbid cigarette smoking: a randomized clinical trial. Jama Psychiatry. 2018;75(2):129–138.
   PubMed Web of Science ®Google Scholar
• Roberts W, Harrison EL, McKee SA. Effects of varenicline on alcohol cue reactivity in heavy drinkers. Psychopharmacol (Berl). 2017;234(18):2737–2745.
   PubMed Web of Science ®Google Scholar
• Walker LC, Berizzi AE, Chen NA, et al. Acetylcholine muscarinic m4 receptors as a therapeutic target for alcohol use disorder: converging evidence from humans and rodents. Biol Psychiatry. 2020;88(12):898–909.
   Web of Science ®Google Scholar
• Berizzi AE, Perry CJ, Shackleford DM, et al. Muscarinic M5 receptors modulate ethanol seeking in rats. Neuropsychopharmacol. 2018;43(7):1510–1517.
   PubMed Web of Science ®Google Scholar
• Moran SP, Maksymetz J, Conn PJ. Targeting muscarinic acetylcholine receptors for the treatment of psychiatric and neurological disorders. Trends Pharmacol Sci. 2019;40(12):1006–1020.
   PubMed Web of Science ®Google Scholar
• Tayebati SK, Amenta F. Choline-containing phospholipids: relevance to brain functional pathways. Clin Chem Lab Med. 2013;51(3):513–521.
   PubMed Web of Science ®Google Scholar
• Arenth PM, Russell KC, Ricker JH, et al. CDP-choline as a biological supplement during neurorecovery: a focused review. PM&R. 2011;3(6):S123–S131.
   Web of Science ®Google Scholar
• Yoon SJ, Lyoo IK, Kim HJ, et al. Neurochemical alterations in methamphetamine-dependent patients treated with cytidine-5′-diphosphate choline: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacol. 2010;35(5):1165–1173.
   PubMed Web of Science ®Google Scholar
• Morley KC, Lagopoulos J, Logge W, et al. Brain N-Acetyl Aspartate and associations with cognitive impairment in alcohol dependent patients. J Clin Exp Neuropsychol. 2020;42(2):111–117.
   PubMed Web of Science ®Google Scholar
• Brown ES, Van Enkevort E, Kulikova A, et al. A randomized, double-blind, placebo-controlled trial of citicoline in patients with alcohol use disorder. Alcohol Clin Exp Res. 2019;43(2):317–323.
   PubMed Web of Science ®Google Scholar
• Williams K. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol. 1993;44(4):851–859.
   PubMed Web of Science ®Google Scholar
• Siggins GR, Martin G, Roberto M, et al. Glutamatergic transmission in opiate and alcohol dependence. Ann N Y Acad Sci. 2003;1003(1):196–211.
   PubMedGoogle Scholar
• Boyce-Rustay JM, Cunningham CL. The role of NMDA receptor binding sites in ethanol place conditioning. Behav Neurosci. 2004;118(4):822–834.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kato H, Tsuda M, et al. Effects of the non-competitive NMDA receptor antagonist ifenprodil on the morphine-induced place preference in mice. Life Sci. 1999;64(12):151–156.
   Web of Science ®Google Scholar
• Lewohl JM, Wilson WR, Mayfield RD, et al. G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action. Nat Neurosci. 1999;2(12):1084–1090.
   PubMed Web of Science ®Google Scholar
• Sugaya N, Ogai Y, Aikawa Y, et al. A randomized controlled study of the effect of ifenprodil on alcohol use in patients with alcohol dependence. Neuropsychopharmacol Rep. 2018;38(1):9–17.
   PubMedGoogle Scholar
• Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, et al. Ketamine for the treatment of addiction: evidence and potential mechanisms. Neuropharmacol. 2018;142:72–82.
   PubMed Web of Science ®Google Scholar
• Das RK, Gale G, Walsh K, et al. Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories. Nat Commun. 2019;10(1):1–10.
   PubMedGoogle Scholar
• Dakwar E, Levin F, Hart CL, et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. 2020;177(2):125–133.
   PubMed Web of Science ®Google Scholar
• Corriger A, Pickering G. Ketamine and depression: a narrative review. Drug Des Devel Ther. 2019;13:3051–3067.
   PubMed Web of Science ®Google Scholar
• Singh I, Morgan C, Curran V, et al. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. Lancet Psychiatry. 2017;4(5):419–426.
   PubMed Web of Science ®Google Scholar
• Sinha R, Fox HC, Hong KA, et al. Enhanced negative emotion and alcohol craving, and altered physiological responses following stress and cue exposure in alcohol dependent individuals. Neuropsychopharmacol. 2009;34(5):1198–1208.
   PubMed Web of Science ®Google Scholar
• Koob GF. Brain stress systems in the amygdala and addiction. Brain Res. 2009;1293:61–75.
   PubMed Web of Science ®Google Scholar
• Kenna GA, Haass‐Koffler CL, Zywiak WH, et al. Role of the α1 blocker doxazosin in alcoholism: a proof‐of‐concept randomized controlled trial. Addict Biol. 2016;21(4):904–914.
   PubMed Web of Science ®Google Scholar
• Haass-Koffler CL, Goodyear K, Zywiak WH, et al. Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. Drug Alcohol Depend. 2017;177:23–28.
   PubMed Web of Science ®Google Scholar
• Fox HC, Anderson GM, Tuit K, et al. Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. Alcohol Clin Exp Res. 2012;36(2):351–360.
   PubMed Web of Science ®Google Scholar
• Wilcox CE, Tonigan JS, Bogenschutz MP, et al. A randomized, placebo-controlled, clinical trial of prazosin for the treatment of alcohol use disorder. J Addict Med. 2018;12(5):339–345.
   PubMed Web of Science ®Google Scholar
• Simpson TL, Saxon AJ, Stappenbeck C, et al. Double-blind randomized clinical trial of prazosin for alcohol use disorder. Am J Psychiatry. 2018;175(12):1216–1224.
   PubMed Web of Science ®Google Scholar
• Petrakis IL, Desai N, Gueorguieva R, et al. Prazosin for veterans with posttraumatic stress disorder and comorbid alcohol dependence: a clinical trial. Alcohol Clin Exp Res. 2016;40(1):178–186.
   PubMed Web of Science ®Google Scholar
• Henckens MJ, Deussing JM, Chen A. Region-specific roles of the corticotropin-releasing factor–urocortin system in stress. Nat Rev Neurosci. 2016;17(10):636.
   PubMed Web of Science ®Google Scholar
• Heilig M, Koob GF. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci. 2018;42(10):399–406.
   Google Scholar
• Zorrilla EP, Logrip ML, Koob GF. Corticotropin releasing factor: a key role in the neurobiology of addiction. Front Neuroendocrinol. 2014;35(2):234–244.
   PubMed Web of Science ®Google Scholar
• Kwako LE, Spagnolo PA, Schwandt ML, et al. The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. Neuropsychopharmacol. 2015;40(5):1053–1063.
   PubMed Web of Science ®Google Scholar
• Schwandt ML, Cortes CR, Kwako LE, et al. The CRF1 antagonist verucerfont in anxious alcohol-dependent women: translation of neuroendocrine, but not of anti-craving effects. Neuropsychopharmacol. 2016;41(12):2818–2829.
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Rothbaum BO, Binder EB, et al. Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials. 2014;15(1):240.
   PubMedGoogle Scholar
• Meyer-Lindenberg A, Domes G, Kirsch P, et al. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci. 2011;12(9):524–538.
   PubMed Web of Science ®Google Scholar
• Hansson AC, Koopmann A, Uhrig S, et al. Oxytocin reduces alcohol cue-reactivity in alcohol-dependent rats and humans. Neuropsychopharmacol. 2018;43(6):1235–1246.
   PubMed Web of Science ®Google Scholar
• Lee MR, Schwandt ML, Sankar V, et al. Effect of alcohol use disorder on oxytocin peptide and receptor mRNA expression in human brain: a post-mortem case-control study. Psychoneuroendocrinol. 2017;85:14–19.
   PubMed Web of Science ®Google Scholar
• Lee MR, Rohn MC, Tanda G, et al. Targeting the oxytocin system to treat addictive disorders: rationale and progress to date. CNS Drugs. 2016;30(2):109–123.
   PubMed Web of Science ®Google Scholar
• Tunstall BJ, Kirson D, Zallar LJ, et al. Oxytocin blocks enhanced motivation for alcohol in alcohol dependence and blocks alcohol effects on GABAergic transmission in the central amygdala. PLoS Biol. 2019;17(4):e2006421.
   PubMed Web of Science ®Google Scholar
• Lee MR, Weerts EM. Oxytocin for the treatment of drug and alcohol use disorders. Behav Pharmacol. 2016;27(8):640–648.
   PubMed Web of Science ®Google Scholar
• King CE, Becker HC. Oxytocin attenuates stress-induced reinstatement of alcohol seeking behavior in male and female mice. Psychopharmacol (Berl). 2019;236(9):2613–2622.
   PubMed Web of Science ®Google Scholar
• Pedersen CA, Smedley KL, Leserman J, et al. Intranasal oxytocin blocks alcohol withdrawal in human subjects. Alcohol Clin Exp Res. 2013;37(3):484–489.
   PubMed Web of Science ®Google Scholar
• Mitchell JM, Arcuni PA, Weinstein D, et al. Intranasal oxytocin selectively modulates social perception, craving, and approach behavior in subjects with alcohol use disorder. J Addict Med. 2016;10(3):182–189.
   PubMed Web of Science ®Google Scholar
• Moller, H-J. Therapy resistance/chronicity, their determinants and potential solutions. Eur Arch Psychiatry Clin Neurosci. 2020;270(1):1–10.
   PubMed Web of Science ®Google Scholar
• Carrasco GA, Van De Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol. 2003;463(1–3):235–272.
   PubMed Web of Science ®Google Scholar
• Claassen CA, Trivedi MH, Rush AJ, et al. Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR⁎D trial. J Affect Disord. 2007;97(1–3):77–84.
   PubMed Web of Science ®Google Scholar
• Katz DA, Locke C, Greco N, et al. Hypothalamic‐pituitary‐adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one‐week randomized Phase 1b trial. Brain Behav. 2017;7(3):e00628.
   PubMed Web of Science ®Google Scholar
• Katz DA, Locke C, Liu W, et al. Single‐dose interaction study of the arginine vasopressin type 1 B receptor antagonist ABT‐436 and alcohol in moderate alcohol drinkers. Alcohol Clin Exp Res. 2016;40(4):838–845.
   PubMed Web of Science ®Google Scholar
• Ryan ML, Falk DE, Fertig JB, et al. A Phase 2, double-blind, placebo-controlled randomized trial assessing the efficacy of ABT-436, a novel V1b receptor antagonist, for alcohol dependence. Neuropsychopharmacology. 2017;42(5):1012–1023.
   PubMed Web of Science ®Google Scholar
• Teesson M, Hall W, Slade T, et al. Prevalence and correlates of DSM-IV alcohol abuse and dependence in Australia: findings of the 2007 national survey of mental health and wellbeing. Addiction. 2010;105(12):2085–2094.
   PubMed Web of Science ®Google Scholar
• Farokhnia M, Faulkner ML, Piacentino D, et al. Ghrelin: from a gut hormone to a potential therapeutic target for alcohol use disorder. Physiol Behav. 2019;204:49–57.
   PubMed Web of Science ®Google Scholar
• Abizaid A, Liu ZW, Andrews ZB, et al. Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest. 2006;116(12):3229–3239.
   PubMed Web of Science ®Google Scholar
• Jerlhag E, Egecioglu E, Dickson SL, et al. Ghrelin stimulates locomotor activity and accumbal dopamine-overflow via central cholinergic systems in mice: implications for its involvement in brain reward. Addict Biol. 2006;11(1):45–54.
   PubMed Web of Science ®Google Scholar
• Jerlhag E, Egecioglu E, Landgren S, et al. Requirement of central ghrelin signaling for alcohol reward. Proc Natl Acad Sci U S A. 2009;106(27):11318–11323.
   PubMed Web of Science ®Google Scholar
• Lee MR, Farokhnia M, Cobbina E, et al. Endocrine effects of the novel ghrelin receptor inverse agonist PF-5190457: results from a placebo-controlled human laboratory alcohol co-administration study in heavy drinkers. Neuropharmacol. 2019;170:107788.
   PubMed Web of Science ®Google Scholar
• Lee MR, Tapocik JD, Ghareeb M, et al. The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study. Mol Psychiatry. 2020;25(2):461–475.
   PubMed Web of Science ®Google Scholar
• Leclercq S, De Timary P, Delzenne NM, et al. The link between inflammation, bugs, the intestine and the brain in alcohol dependence. Transl Psychiatry. 2017;7(2):e1048.
   PubMedGoogle Scholar
• Crews FT, Lawrimore CJ, Walter TJ, et al. The role of neuroimmune signaling in alcoholism. Neuropharmacol. 2017;122:56–73.
   PubMed Web of Science ®Google Scholar
• Ray L, Bujarski S, Shoptaw S, et al. Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: a randomized, placebo-controlled, human laboratory trial. Neuropsychopharmacol. 2017;42(9):1776–1788.
   PubMed Web of Science ®Google Scholar
• Quintanilla M, Morales P, Ezquer F, et al. Commonality of ethanol and nicotine reinforcement and relapse in Wistar-derived UChB rats: inhibition by N-acetylcysteine. Alcohol Clin Exp Res. 2018;42(10):1988–1999.
   PubMed Web of Science ®Google Scholar
• Morley KC, Baillie A, Van Den Brink W, et al. N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: rationale for further research. Expert Opin Investig Drugs. 2018;27(8):667–675.
   PubMed Web of Science ®Google Scholar
• Karimi-Haghighi S, Dargahi L, Haghparast A. Cannabidiol modulates the expression of neuroinflammatory factors in stress- and drug-induced reinstatement of methamphetamine in extinguished rats. Addict Biol. 2020;25(2). DOI:10.1111/adb.12740
   PubMed Web of Science ®Google Scholar
• Tunstall BJ, Lorrai I, McConnell SA, et al. Probenecid reduces alcohol drinking in rodents. is pannexin1 a novel therapeutic target for alcohol use disorder? Alcohol Alcohol. 2019;54(5):497–502.
   PubMed Web of Science ®Google Scholar
• Norman J, Anderson S. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia. Nat Sci Sleep. 2016;8:239–247.
   PubMed Web of Science ®Google Scholar
• Kim AK, Brown RM, Lawrence AJ. The role of orexins/hypocretins in alcohol use and abuse: an appetitive-reward relationship. Front Behav Neurosci. 2012;6:78.
   PubMed Web of Science ®Google Scholar
• Walker LC, Lawrence AJ. The role of orexins/hypocretins in alcohol use and abuse. Curr Top Behav Neurosci. 2017;33:221–246.
   PubMedGoogle Scholar
• Campbell EJ, Norman A, Bonomo Y, et al. Suvorexant to treat alcohol use disorder and comorbid insomnia: plan for a phase II trial. Brain Res. 2020;1728:146597.
   PubMed Web of Science ®Google Scholar
• Litten RZ, Falk DE, Ryan ML, et al., Five priority areas for improving medications development for alcohol use disorder and promoting their routine use in clinical practice. Alcohol Clin Exp Res. 44(1): 23–35. 2020. .
   PubMed Web of Science ®Google Scholar
• Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv. 2019;5(9):eaax4043.
   PubMed Web of Science ®Google Scholar
• Morley KC, Logge W, Pearson SA, et al. National trends in alcohol pharmacotherapy: findings from an Australian claims database. Drug Alcohol Depend. 2016;166:254–257.
   PubMed Web of Science ®Google Scholar
• Morley KC, Logge W, Pearson SA, et al. Socioeconomic and geographic disparities in access to pharmacotherapy for alcohol dependence. J Subst Abuse Treat. 2017;74:23–25.
   PubMed Web of Science ®Google Scholar